STAT July 31, 2024
Good morning. We have a new investigation out today about how Mount Sinai in New York mounted an aggressive campaign to stifle debate over its controversial brain research. Check it out here.
And let’s get into the biotech news.
The need-to-know this morning
- A marketing application for a new type of non-opioid pain medication developed by Vertex Pharmaceuticals was accepted by the FDA, with an approval decision data set for Jan. 30, 2025.
- GSK reported second-quarter earnings.
- Fibrogen reported negative outcomes from two clinical trials in pancreatic cancer. The company said it will discontinue development of the drug, called pamrevlumab, and reduce its workforce by 75%.
Eisai, Biogen argue for long-term use of Leqembi
Eisai and Biogen reported...
Today's Sponsors
Today's Sponsor